GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nephros NEPH · USD

Consumer Discretionary · US listing · 🇺🇸 United States

Compare

3.00

+7.53%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Nephros

From its filings with the US Securities and Exchange Commission

SEC filings

Nephros is based in South Orange, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker NEPH. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $18.8m and net income of $1.2m. At that date it held total assets of $13.6m and shareholders' equity of $10.2m. By business, Product [Member] brought in 97.0% of revenue, followed by Royalty and Other Revenues [Member] at 3.0% and Service [Member] at 2.8%.

Read the filing on SEC.gov ↗

Company facts

Sector
Consumer Discretionary
Industry
Household Durables
Listed since
21 Sept 2004
Employees
27
Website
nephros.com ↗
Head office
380 LACKAWANNA PLACE, SOUTH ORANGE, NJ, 07079
Incorporated in
DE
Classification
Surgical & Medical Instruments & Apparatus
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Robert BanksPresident, Chief Executive Officer, Director, since 2023$410,172
  • Ms. Judith KrandelChief Financial Officer$148,704
  • Mr. Arthur AmronDirector$49,478
  • Mr. Joseph HarrisIndependent Director$45,524
  • Mr. Oliver SpandowIndependent Director$65,388

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Nephros Inc develops advanced water purification filters for medical and commercial use.
  • Nephros Inc's Renal Products segment focuses on hemodiafiltration systems for ESRD patients.
  • Nephros Inc operates through two key segments: Water Filtration and Renal Products.

Weaknesses

  • Nephros Inc has only 27 employees, limiting operational capacity.
  • Nephros Inc's IPO was in 2004, indicating limited recent market presence.
  • Nephros Inc's subsidiaries include Biocon 1, LLC and Aether Water Systems, LLC.

Opportunities

  • Nephros Inc can expand its water filtration products into military and outdoor markets.
  • Nephros Inc's Renal Products segment targets hospitals and dialysis centers for growth.
  • Nephros Inc's ultrafiltration products serve home and portable dialysis machines.

Threats

  • Nephros Inc faces competition from established medical device companies in the Renal Products segment.
  • Nephros Inc's small employee count may hinder rapid market expansion.
  • Nephros Inc's focus on niche medical applications could limit broader market reach.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.